Trial Profile
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Catequentinib (Primary) ; Dacarbazine
- Indications Alveolar soft part sarcoma; Leiomyosarcoma; Soft tissue sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- Acronyms APROMISS
- Sponsors Advenchen Laboratories
- 29 Jan 2024 Planned End Date changed from 1 Apr 2024 to 1 Jun 2025.
- 29 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 27 Jul 2023 Planned End Date changed from 1 Apr 2023 to 1 Apr 2024.